Others

<p>Applications A compound present in olive oil. An important fine chemical intermediate with broad prospects for application development.<br>References Shu, Y., et al.: Guangdong Huagong, 37, 108 (2010), Papadopoulos, G., et al.: J Am Oil Chem Soc, 68, 669 (1991),<br></p>

<p>Applications Useful for diagnostic determination of Melamine and related compounds in kidney tissue.<br>References Mast, R., et al.: Food Chem. Toxicol., 21, 807 (1983), Yokley, R., et al.: J. Agric. Food Chem., 48, 3352 (2000), Ehling, S., et al.: Food Addit. Contam., 24, 1319 (2007), Vail, T., et al.: J. Anal. Toxicol., 31, 304 (2007),<br></p>

<p>Applications A labelled metabolite of Toluene.<br>References Gargas, M., et al.: Toxicol. Appl. Pharmacol., 98, 87 (1989), Commandeur, J., et al.: Pharmacol. Rev., 47(2), 271 (1995), Campo, P., et al.: Neurotoxicol. Teratol., 21, 427 (1999), Lohse, C., et al.: J. Agr. Food Chem., 48, 5913 (2000),<br></p>

<p>Applications (E)-Isomer of Entacapone polymorphic form A. Peripherally acting inhibitor of catechol-O-methyl transferase (COMT), an enzyme involved in the metabolism of catecholamine neurotransmitters and related drugs. Antiparkinsonian.<br>References Karlsson, M., et al.: J. Pharm. Biomed. Anal., 10, 593 (1992); Nissinen, E., et al.: Arch. Pharmacol., 346, 262 (1992); Wikberg, T., et al.: Eur. J. Drug Metab. Pharmacokinet., 18, 359 (1993);<br></p>

<p>Stability Hygroscopic<br>Applications Food Red No. 102 is an artificial coloring food additive. Dye. Dyes and metabolites, Environmental Testing<br>References McCann, D. et al.: Lancet. 370, 1560 (2007); Kim, Y. et al.: Text. Res. J., 71, 318 (2001);<br></p>

<p>Applications N-(3-(3-Cyano-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-5-yl)phenyl)-N-ethylacetamide is an impurity of Zaleplon (Z145000), Selective non-benzodiazepine GABAA receptor agonist.<br>References Allen, D., et al.: Eur. J. Clin. Pharmacol., 45, 313 (1993), Beer, B., et al.: J. Clin. Pharmacol., 34, 335 (1994), Rosen, A.S., et al.: Biopharm. Drug Dispos., 20, 171 (1999), Elie, R., et al.: J. Clin. Psychiatry, 60, 536 (1999), Heydorn, W.E., et al.: Expert Opin. Invest. Drugs, 9, 841 (2000)<br></p>

<p>Stability Hygroscopic<br>Applications By-product in the preparation of a Lorazepam metabolite.<br></p>

<p>Applications Carfilzomib (2R,4S)-Diol is a derivative of Carflizomib (C183460), a second-generation proteasome inhibitor that is used as a treatment in relapsed and refractory multiple myeloma.<br>References Fostier, K., et al.: Oncotargets. Therap., 5, 237 (2012); Geurink, P.P., et al.: J. Med. Chem., 56, 1262 (2013); McCormack, P.L., et al.: Drugs., 72, 2023 (2012);<br></p>

<p>Applications A silicon based compound that can be used to create potentially biocompatible materials. Used as a monomer in the synthesis of long chain polysiloxane structures. Used in the methylation of mercury(II) salts.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Radeva, E. et al.: J. Optoelec. Adv. Mat., 11, 1432 (2009); Gandhiraman, R.P. et al.: Plama Proc. Polym., 11, 1432 (2009); Watanabe, N. et al.: Ecotoxic. Env. Safety, 11, 174 (1986);<br></p>

<p>Applications Mixture of labelled Tamoxifen and its (E)-isomer.<br></p>

<p>Applications Cyclopyrrolone member of a family of non-benzodiazepine GABAA receptor agonists. This is a controlled substance (depressant) in the US but not in Canada. Sedative, hypnotic.<br>References Noble, S., et al.: Drugs, 55, 277 (1998), Musch, B., et al.: Int. J. Clin. Psychopharmacol., 5, 147 (1990),<br></p>

<p>Impurity Lorazepam USP Related Compound C<br>Applications An impurity of the anxiolytic and anticonvulsant drug Lorazepam (L469850). Lorazepam USP Related Compound C.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Wang, H. et al.: Yao. Fen. Zaz., 29, 1985 (2009); Dabas, P.C. et al.: Drug Dev. Ind. Pharm., 14, 133 (1988);<br></p>

<p>Applications A labelled metabolite of Diazepam; it had a much weaker anticonvulsant effect.<br>References Hara, T., et al.: J. Med. Chem., 21, 263 (1978),<br></p>

<p>Applications Silodosin is an α1a-adrenoceptor antagonist. It is used in treatment of benign prostatic hypertrophy.<br>References (1) Shibata, K., et al.: Mol. Pharmacol., 48, 250 (1995) (2) Murata, S., et al.: J. Urol., 164, 578 (2000)<br></p>

<p>Applications Palbociclib-d4 is an isotope labelled compound of Palbociclib (P139900). Palbociclib (P139900) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.<br>References Finn, R., et al.: Breast Cancer Res., 11, 5 (2009)<br></p>

<p>M04074 - 5-Bromo-6-chloro-3-indolyl beta-D-glucuronide cyclohexylammonium salt</p>

<p>Applications Selective non-benzodiazepine GABAA receptor agonist.<br>References Allen, D., et al.: Eur. J. Clin. Pharmacol., 45, 313 (1993), Beer, B., et al.: J. Clin. Pharmacol., 34, 335 (1994), Rosen, A.S., et al.: Biopharm. Drug Dispos., 20, 171 (1999), Elie, R., et al.: J. Clin. Psychiatry, 60, 536 (1999), Heydorn, W.E., et al.: Expert Opin. Invest. Drugs, 9, 841 (2000)<br></p>

<p>Applications Zaleplon Formide is an impurity of Zaleplon (Z145000), a selective non-benzodiazepine GABAA receptor agonist.<br>References Radl, S., et al.: J. Heterocycl. Chem, 47, 276 (2010); Allen, D., et al.: Eur. J. Clin. Pharmacol., 45, 313 (1993); Beer, B., et al.: J. Clin. Pharmacol., 34, 335 (1994); Rosen, A.S., et al.: Biopharm. Drug Dispos., 20, 171 (1999)<br></p>

<p>Stability Hygroscopic<br>Applications Used as an antiparkinsonian and antispasmodic.<br>References Rohde, H., et al.: Fortschr. Med., 100, 2023 (1982), Kornhuber, J., et al.: Eur. J. Pharmacol., 166, 589 (1989), Gortelmeyer, R. and Erbler, H.: Arzneimittel-Forsch., 42, 904 (1992)<br></p>

<p>Applications MDV 3100 is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. MDV 3100 has also been shown to induce tumor cell apoptosis, and has no agonist activity. MDV 3100 is a candidate for the treatment of castration-resistant prostate cancer.<br>References Scher, H.I. et al.: Lancet, 375, 1437 (2010); Bellmunt, J. et al.: Ther. Adv. Med. Oncol., 2, 189 (2010); Ryan, C.J. et al.: J. Clin. Oncol., 29, 3651 (2011);<br></p>